The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.
Ferraccioli, G., Tolusso, B., Gremese, E., Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: Pros and cons?, <<ARTHRITIS RESEARCH & THERAPY>>, 2016; 18 (1): 126-N/A. [doi:10.1186/s13075-016-1022-1] [http://hdl.handle.net/10807/94041]
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: Pros and cons?
Ferraccioli, GianfrancoPrimo
;Tolusso, BarbaraSecondo
;Gremese, ElisaUltimo
2016
Abstract
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
